Skip to main content

Moderna Is Financing an 'Unbelievable Opportunity' With Vaccine Sales: Cramer

Publish date:
Video Rating:
Video Duration:

Moderna  (MRNA) - Get Free Report reported adjusted earnings of $6.46 per share on revenue of $4.35 billion. The company boosted its forecast for 2021 vaccine sales to around $20 billion after reporting $4.2 billion in vaccine sales for the quarter. 

Despite the strong result, Moderna dipped over 2% to $409.45 in intraday trading Thursday. 

Is it a buying opportunity? 

Jim Cramer told Action Alerts PLUS senior analyst Jeff Marks that investors will be clambering for Moderna stock as the company uses strong COVID vaccine sales to finance future research. 

Catch his full take on Moderna as well as Pfizer  (PFE) - Get Free Report and AbbVie  (ABBV) - Get Free Report in the video above. 

Recap TheStreet Live: Everything Jim Cramer Is Watching 8/5/21

Related Videos